聚合物偶联 IL-15 NKTR-255 与 CAR-T 细胞治疗协同激活内源性抗肿瘤免疫并改善肿瘤控制 NKTR-255, a polymer-conjugated IL-15, synergizes with CAR-T cell therapy to activate endogenous anti-tumor immunity and improve tumor control. PubMed 2025/12/15 发表bioRxiv 靶点:CD19靶点:ROR1技术:CAR-T技术:NK 细胞肺癌B 细胞恶性肿瘤
ICOS 和 OX40 串联共刺激增强 CAR-T 细胞细胞毒性并促进 T 细胞持久性表型 ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype. PubMed 2023/08/18 发表Front OncolQ2 · IF 3.4(JCR 2025) 靶点:CD19靶点:ROR1技术:CAR-T实体瘤淋巴瘤白血病
B 细胞淋巴系统恶性肿瘤的 CAR-T 细胞治疗:识别 CD19 之外的靶点 CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19. PubMed 2022/12/15 发表Hematol Oncol Stem Cell Ther 靶点:CD19靶点:CD20靶点:CD22技术:CAR-T急性淋巴细胞白血病非霍奇金淋巴瘤
2022 年套细胞淋巴瘤:分子发病机制、风险分层、临床策略及当前与新型治疗的综合更新 Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatment PubMed 2022/05/01 发表Am J HematolQ1 · IF 9.4(JCR 2025) 靶点:CD19靶点:CD20靶点:CD70技术:CAR-T技术:双特异性抗体套细胞淋巴瘤淋巴瘤
复发/难治性套细胞淋巴瘤的治疗选择 Therapeutic options for relapsed/refractory mantle cell lymphoma. PubMed 2022/02/03 发表BloodQ1 · IF 23.9(JCR 2025) 靶点:CD19靶点:ROR1技术:CAR-T技术:双特异性抗体套细胞淋巴瘤非霍奇金淋巴瘤